Tango Therapeutics (TNGX) Total Current Liabilities (2020 - 2026)

Tango Therapeutics' Total Current Liabilities history runs 7 years deep, the most recent figure standing at $14.3 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities fell 60.1% year-over-year to $14.3 million in Q1 2026; TTM through Mar 2026 was $14.3 million, a 60.1% decrease from a year earlier, with the FY2025 full-year figure at $21.7 million, down 43.2% from the prior year.
• Total Current Liabilities slipped to $14.3 million in Q1 2026 per TNGX's latest filing, from $21.7 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $55.5 million in Q4 2022 and bottomed at $14.3 million in Q1 2026.
• The 5-year median for Total Current Liabilities is $42.8 million (2024), against an average of $40.0 million.
• Across the five-year window, Total Current Liabilities surged 12885.32% in 2022 and slumped 60.1% in 2026, its largest moves.
• Year by year, Total Current Liabilities stood at $55.5 million in 2022, then declined by 17.3% to $45.9 million in 2023, then declined by 16.91% to $38.2 million in 2024, then slumped by 43.2% to $21.7 million in 2025, then tumbled by 33.9% to $14.3 million in 2026.
• Per Business Quant, the three latest TNGX Total Current Liabilities figures stand at $14.3 million (Q1 2026), $21.7 million (Q4 2025), and $18.4 million (Q3 2025).